UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 13, 2025

GlycoMimetics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware	**001-36177**	**06-1686563**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

9708 Medical Center Drive
Rockville, MD 20850
(Address of Principal Executive Offices)

(240) 243-1201
(Registrant's telephone number, including area code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☒ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Common Stock, $0.001 par value	GLYC	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 12, 2025, GlycoMimetics, Inc. ("GlycoMimetics") and Crescent Biopharma, Inc. ("Crescent") updated the investor presentation used by them in connection with their proposed merger, which investor presentation is furnished as Exhibit 99.1 hereto and incorporated herein.

No Offer or Solicitation

This Current Report on Form 8-K and the exhibits filed or furnished herewith are not intended to and do not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the proposed transaction or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.

NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS CURRENT REPORT ON FORM 8-K AND THE EXHIBITS FILED OR FURNISHED HEREWITH ARE TRUTHFUL OR COMPLETE.

Important Additional Information About the Proposed Transaction Will be Filed with the SEC

This Current Report on Form 8-K and the exhibits filed or furnished herewith are not substitutes for the Proxy Statement or for any other document that GlycoMimetics may file with the SEC in connection with the proposed transaction. In connection with the proposed transaction between GlycoMimetics and Crescent, GlycoMimetics intends to file relevant materials with the SEC, including a proxy statement of GlycoMimetics. GLYCOMIMETICS URGES INVESTORS AND STOCKHOLDERS TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT GLYCOMIMETICS, CRESCENT, THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and stockholders will be able to obtain free copies of the Proxy Statement and other documents filed by GlycoMimetics with the SEC (when they become available) through the website maintained by the SEC at *www.sec.gov*. In addition, investors and stockholders should note that GlycoMimetics communicates with investors and the public using its website (*www.glycomimetics.com*) and the investor relations website (*www.glycomimetics.com/investor-relations*) where anyone will be able to obtain free copies of the Proxy Statement and other documents filed by GlycoMimetics with the SEC and stockholders are urged to read the Proxy Statement and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed transaction.

Participants in the Solicitation

GlycoMimetics, Crescent and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from stockholders in connection with the proposed transaction. Information about GlycoMimetics' directors and executive officers including a description of their interests in GlycoMimetics is included in GlycoMimetics' most recent definitive proxy statement, as filed with the SEC on April 1, 2024. Additional information regarding these persons and their interests in the proposed transaction will be included in the Proxy Statement relating to the proposed transaction when it is filed with the SEC. These documents can be obtained free of charge from the sources indicated above.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Investor Presentation, dated January 2025
104	Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GLYCOMIMETICS, INC.
(Registrant)

By: /s/ Brian M. Hahn
Name: Brian M. Hahn
Title: Senior Vice President and Chief Financial Officer

Date: January 13, 2025

Exhibit 99.1


CRESCENT
BIOPHARMA
Crescent Biopharma Overview
January 2025

Disclaimer

This presentation is for informational purposes only and only a summary of certain information related to the Company. It does not purport to be complete and does not contain all information that a in making an investment decision. The information contained herein does not constitute investment, legal, accounting, regulatory, taxation or other advice, and the information does not take into acc or legal, accounting, regulatory, taxation or financial situation or particular needs. Investors must conduct their own investigation of the investment opportunity and evaluate the risks of acquiring t such investor's independent examination and judgment as to the prospects of the Company as determined from information in the possession of such investor or obtained by such investor from the and risks involved.

Statements in this presentation are made as of the date hereof unless stated otherwise herein, and neither the delivery of this presentation at any time, nor any sale of Securities, shall unde implication that the information contained herein is correct as of any time subsequent to such date. The Company is under no obligation to update or keep current the information contained in this warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein, and any relia your sole risk. The Company, its affiliates and advisors do not accept any liability whatsoever for any loss howsoever arising, directly or indirectly, from the use of this document or its contents, or with the Offering.

Forward-Looking Statements

Certain statements contained in this presentation that are not descriptions of historical facts are "forward-looking statements." When we use words such as "potentially," "could," "will," "projected," " "estimated" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not guarantees of future performance an that may cause our actual results to differ materially from our expectations discussed in the forward-looking statements. This may be a result of various factors, including, but not limited to: our ma hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the Offering and the transactions contemplated by the Merger Agreement, and the expe or opportunities and related timing with respect thereto, expectations regarding or plans for discovery, preclinical studies, clinical trials and research and development programs and therapies; ex proceeds and the time period over which our capital resources will be sufficient to fund our anticipated operations; and statements regarding the market and potential opportunities for solid tum forward-looking statements, expressed or implied, included in this presentation are expressly qualified in their entirety by this cautionary statement. You are cautioned not to place undue reliance on Except as otherwise required by applicable law, we disclaim any duty to update any forward-looking statements, all of which are expressly qualified by this cautionary statement, to reflect events or this presentation.

Industry and Market Data

Market and industry data and forecasts used in this presentation have been obtained from independent industry sources as well as from research reports prepared for other purposes. Although we b to be reliable, we have not independently verified the data obtained from these sources and we cannot assure you of the accuracy or completeness of the data. Forecasts and other forward-looking sources are subject to the same qualifications and uncertainties as the other forward-looking statements in this presentation. Statements as to our market and competitive position data are based on to us, as well as management's internal analyses and assumptions regarding the Company, which involve certain assumptions and estimates. These internal analyses have not been verified by any can be no assurance that the assumptions or estimates are accurate. While we are not aware of any misstatements regarding our industry data presented herein, our estimates involve risks and change based on various factors. As a result, we cannot guarantee the accuracy or completeness of such information contained in this presentation.

CRESCENT BIOPHARMA

Crescent Biopharma aims to advance the next wave of innovation in cancer therapy

Crescent's pipeline consists of **potentially best-in-class therapies for the treatment of solid tu**

- Crescent is the **fifth company** launched with assets **discovered in-house** by Paragon Therapeutics, a leading biotech incubator founded by Fairmount Funds in 2021.
  - Prior companies founded with Paragon assets have **collectively raised >$2B and generated significant value**.
- **~$200 million financing** in October 2024 anticipated to fund operations through 2027.

Program	MoA	Stage		
		Discovery	IND-enabling	Clinical
CR-001[1]	**PD-1 x VEGF** *(same cooperative MoA as ivonescimab)*	→		**4Q25**[2]
CR-002	**Undisclosed #1** *(ADC, Topo I payload)*	→		Mid-26
CR-003	**Undisclosed #2** *(ADC, Topo I payload)*	→		

CRESCENT BIOPHARMA

Notes: [1]Anticipated expiration for filed provisional patent is 2045+
[2]IND timing accelerated vs. prior guidance YE25/1Q26

Crescent is advancing three highly impactful oncology pro with best-in-class potential

CR-001

PD-1 x VEGF cooperative tetravalent bsAb;
same MoA as ivonescimab



- Designed to **reproduce ivonescimab's established pharmacology**.
- **Pipeline in a program opportunity** across solid tumor indications, with potential to **move to frontline use in the $50B+** PD-(L)1 immunotherapy market.
- **IND expected 4Q25**.
- **Interim PoC data expected 2H26**.

CR-002 & CR-003

ADCs with topoisomerase inhibitor pa
potentially best-in-class



- Two unique, targets with potential ac as single age
- Each has po synergize w combination driving clinic
- Both utilize t modality cy topoisomera
- **CR-002 IND**
- **Interim PoC 2027**.

CRESCENT BIOPHARMA

Multiple ways to win: Crescent pipeline enables optionality differentiating combination therapies

Optimized Novel Monotherapies

Engineered for:

- Best-in class efficacy
- Efficacy across solid tumors
- Pharmacokinetics
- Safety
- Stability
- Developability

Synergistic Combination App



Selected for:

- Mechanism of action syn
- Efficacy in overlapping solid
- Broad utility

CRESCENT BIOPHARMA

Crescent leverages two key advances in oncology for next-generation combinations within unique portfolio

Two revolutions underway in oncology:

- Immuno-oncology is potentially moving from PD-(L)1 to cooperative PD-1 x VEGF.
- Chemo is moving from systemic toxins to tumor-targeted toxins via improved ADCs.

Crescent is developing leading assets in both categories, designed to combine for maximum efficacy in priority indications.



CRESCENT BIOPHARMA

PD-(L)1-targeted therapies, annualizing $50B+, have transfo oncology – with Keytruda now the best-selling drug in the v

PD-(L)1 inhibitors have **significantly prolonged survival**, **shifting 1L treatment** to immunotherapy

- For example, in 1L NSQ NSCLC, addition of pembrolizumab to chemo **significantly improved mOS** (**NR vs 11.3 months**[1] with a **HR of 0.49**).



PD-(L)1-targeted therapies are **one of the largest** with **Keytruda (pembrolizumab) the domin**

anti-PD-(L)1 global sales



Keytruda alone is **approved in 20+ oncology indications** with expected revenue of **~$30B in 2024**.

CRESCENT BIOPHARMA

Notes: 1. 5-year followup demonstrated mOS of 22.0 vs 10.6 months. NSQ: Non-squamous. NSCLC: Non-small cell lung cancer. mOS: median overall survival.
Sources: 2018 Gandhi (NEJM); 2023 Garassino (J Clin Oncol); GlobalData; FactSet; Pembrolizumab FDA Label

Ivonescimab, a cooperative PD-1 x VEGF bispecific, double progression-free survival vs. Keytruda in a P3 NSCLC trial

Ivonescimab is the **first drug to demonstrate superiority** in PFS **over pembrolizumab in a randomized Phase 3**



Ivonescimab's novel **raises the bar on efficacy**

1. **Broader efficacy**: Ivonescima benefit **in patients where ant has historically been modes** PD-(L)1^{low}).

	PD-L1^{low} (*TPS 1-49%*)	PD-L1^{high} (*TPS ≥50%*)	squ
HR	0.54	0.46	

2. **Promising safety**: Ivonescim **than expected** versus anti-VE This suggests a **differentiate** cooperativity-driven tissue targ

Dual blockade of PD-1 and VEGF through a **cooperative bispecific antibody** has led to **unprecedented clinical** demonstrating superiority to pembrolizumab… and a **$15B+ market cap for ivo's ex-China sponsor, Summit Ther**

CRESCENT BIOPHARMA

Notes: HR: hazard ratio. PFS: progression-free survival. AE: adverse event. NSQ: Non-squamous SQ: Squamous. Akeso has licensed ivonescimab to Summit in North America, South America, Europe, Africa, Middle East, and Japan. Akeso maintains rights in Asia (ex-Japan / Middle East) and in Oceania.
Sources: 2024 Zhou (WCLC Presentation on HARMONi-2); Summit Therapeutics; 2018 Paz-Area (NEJM); 2019 Mok (Lancet); 2022 De Castro Jr (J Clin Oncol); Avastin Label

CR-001

Cooperative, tetravalent
PD-1 x VEGF bispecific antibody

Ivonescimab's novel, cooperative MoA hypothesized to driv enhanced anti-tumor activity while maintaining tolerability

A VEGF drives **tumor angiogenesis** and PD-L1 expression **suppresses T cells**



B Ivo's **cooperative binding** blocks PD-1 / PD-L1 interactions and inhibits VEGF



✓**Cooperativity**: VEGF bi ivonescimab **increases af** *vice versa*, enhancing **bot and VEGF-signaling bloc** explain the **cross-trial ou** ivonescimab vs. an anti-P combination.



✓**Tumor targeting**: PD-1 VEGF inhibition in the TM **sparing healthy tissue** a

Dual blockade of PD-1 and VEGF through a **novel tetravalent bispecific format with cooperative binding effects** has led to **unprecedented clinical results** in third party trials.

CRESCENT BIOPHARMA

Notes: AE: adverse event. TME: Tumor microenvironment
Sources: 2023 Zhong (SITC Poster); Summit Therapeutics

CR-001 is a highly potent PD-1 x VEGF bsAb designed to recapitulate ivonescimab's cooperative pharmacology

Same design as ivonescimab

- Pairs anti-VEGF IgG & anti-PD-1 scFvs
- Avoids risk of alternative, clinically unprecedented constructs (e.g., VEGF trap, anti-PD-L1 IgG, ADCC)

Highly potent & stable scFvs

- Designed to be the best possible anti-PD-1 epitope / binding domain
- Anti-PD-1s have historically outperformed anti-PD-L1s in meta-analyses of solid tumor studies
- Contains proprietary engineering to enable functional and stable scFvs



CR-001

Potential for reduced

- Cooperative binding
  VEGF activity in TM
  risks in healthy tissue
- Identical VEGF poter
  safety

Effector-null human

- Equivalent to ivones
- ADCC carries additio

Designed to match iv

- Native FcRn binding
  distribution and elir
  ivonescimab

CRESCENT BIOPHARMA

CR-001 replicates ivonescimab's cooperative effect, with gr
binding to and inhibition of PD-1 signaling in presence of V

CR-001 lead, like ivonescimab, is **more potent** in an NFAT reporter assay **in the presence of VEGF**…



… and also **increases PD-1 bindi**
PD-1+ Jurkat cells **in the presence of**



CR-001 lead **demonstrates same cooperative effect as ivonescimab** across multiple assays.

CRESCENT BIOPHARMA

Notes: Ivonescimab generated internally based on published sequence. PD-1 / PD-L1 signaling inhibition measured in RLU (relative light units), a measure of luminescence that increases with greater inhibition. PD-1 binding measured in MFI (mean fluorescence intensity), a measure of fluorescence that increases with binding and is measured via FACS.
Sources: Internal data

Replicating ivonescimab's tetravalent format and cooperati stable scFvs, requires complex protein engineering

Standard mAbs can be improved with **established protein engineering approaches**…

CDRs improved via diversification and/or affinity maturation to maximize potency



Fc engineering tunes **ADCC, CDC, half-life**, etc.

… but **ensuring cooperative effect, stability, and develo** of tetravalent PD-(L)1 x VEGF bispecific antibody is more



IgG forn dimer re **chain**; c **may alt** kinetics geometr

scFv format can **require significant engineering** to ensure stability

Fc silencin risk of AEs

CR-001 has novel composition of matter IP related to proprietary, stabilized scFvs

Leading **unstable** scFv forr hamperi

Ivonescimab's **unique structure and geometry** – and resulting **cooperative function** – is **challenging to repli alternative constructs risk not reproducing** ivonescimab's superior **efficacy and safety** in clinical practice

CRESCENT BIOPHARMA

CR-001 has potential to transform SoC across a multitude o oncology indications, with numerous first-in-class opportu



CRESCENT BIOPHARMA

Notes: EGFRm = mutant epidermal growth factor receptor.
Sources: Keytruda Label; Opdivo Label; Tecentriq Label; Imfinzi Label; Libtayo Label; Bavencio Label; Jemperli Label; Loqtorzi Label; Zynyz Label; Avastin Label; Cyramza Label; Lenvima Label; Votrient Label

Development programs across key late-stage competitors i numerous P3s with PFS & OS readouts, paving the way for

Company	Program	Indication	Population	Combo	Phase	Timing
Akesobio	 *Ivonescimab (China / Australia)*	mNSCLC	★ 1L PD-L1+	None	3	OS readout **expected in 20**
			★ 1L squamous	Chemo	3	OS readout **expected i**
Summit therapeutics	 *Ivonescimab (Global)*	mNSCLC	★ 1L NSQ & SQ	Chemo	3	OS readout **expected in 2027**
			★ 1L PD-L1+*	None	3	To be announced
BIONTECH	 *BNT327 (Global)*					To be announced
						To be announced
						SCLC
						TNBC
						NSCLC

*Multiple global **Phase 2/3s and Phase 3s planned between Summit, BioNTech, and Merck***

Multiple Phase 3s across leading PD-(L)1 x VEGF programs, with **similar expected cooperativi CR-001**, should **generate a multitude of PFS & OS catalysts** for years to come

CRESCENT BIOPHARMA

*Summit has announced P3 in 1L PD-L1+ NSCLC, monotherapy vs. pembro, but has not released trial details.
Notes: List of trials is not exhaustive. NSCLC = non-small cell lung cancer; TNBC = triple negative breast cancer; SCLC = small cell lung cancer; NSQ = non-squamous; SQ = squamous.
PFS and OS readouts estimated based on PEP (primary endpoints) and completion dates listed on ClinicalTrials.gov.
Sources: ClinicalTrials.gov; Company websites; Company presentations

Parallel clinical development paths offer potential for both first-in-class and lower risk opportunities for CR-001



CR-001

1

Focus on potential first-in-class opportunities with rapid path to market
(i.e., efficient development strategy, anticipated likelihood of PFS and OS success)

- Numerous indications with clinically meaningful anti-PD-(L)1 +/- VEGF efficacy and p
to combine with chemo / orthogonal MoAs.

2

Plan to rapidly follow ivonescimab in indications where clinical validation vs. anti-PD-(L)1 is highly differentiating

POTENTIAL INDICATION

NSCLC

TNBC

- High conviction that CR-001 can replicate ivonescimab's efficacy given similar construct & equivalent MoA.

CRESCENT BIOPHARMA

CR-001 Phase 1 data offer potential for early de-risking – a for a solid tumor oncology program

Phase 1 interim proof-of-concept data are a potentially **significant value-generating event** for CR-001.

- Preliminary data from early Phase 1 cohorts **provide substantial validation of program** because CR-001's **structural preclinical data are similar to ivonescimab.**
- Early Phase 1 data, as single agent and in combination with SoC, rapidly enable late-stage development **in multiple so types, unlocking broad first-in-class and fast-follower opportunities**.
- CR-001 is **markedly differentiated** from **novel constructs disconnected from ivonescimab's MoA**. Alternative forma **significantly more patients' worth of safety and efficacy data** in tumor-specific expansion cohorts and/or Phase 2s t conviction before initiating Phase 3s.

ILLUSTRATIVE



CR-001

IND — 4Q25

Phase 1 *(solid tumor all-comers)*

- **Key derisking preliminary data:**
  - ✓ PK
  - ✓ Safety
  - ✓ Efficacy (e.g., ORR)

PoC — *Interim 2H26*

Phase 3s *(validated indications)*

Phase 2/3s *(first-in-class opportunities)*

- Higher confidence to fund and **accelerate CR-001 into P3s** after P1 interim data, given **replication of ivonescimab's cooperative pharmacology**

High conviction in CR-001's clinical profile can be **reached in ~9-12 months** from Phase 1 initiation, offering potential for significant **early value inflection**.

CRESCENT BIOPHARMA

Scarcity of known constructs with potential to exhibit ivonescimab-like cooperative pharmacology and design





	Anti-PD-1 scFv-based		Anti-PD-1 VHH-based	Anti-PI
Program	**CR-001**	**Ivonescimab**	**LM-299**	**BNT**
Company	CRESCENT BIOPHARMA	Summit therapeutics, Akesobio	MERCK, LaNova 礼新医药	BIONTE
Stage	Preclinical	Phase 3 (Global)	Phase 1/2 initiation (China)	Phase 2 (G
Anti-VEGF IgG	Bevacizumab	Bevacizumab	Bevacizumab	B
Anti-PD-(L)1	Anti-PD-1 scFvs	Penpulimab scFvs	Novel anti-PD-1 VHHs	Novel
Fc function	Fc null, to avoid potential AEs	Fc null, to avoid potential AEs	Fc null, to avoid potential AEs	Fc null, to
Cooperative pharmacology	✓	✓	Expected (not disclosed); unclear impact of VHH structure	Expect unclear i

Examples of alternative constructs



- Anti-PD-L1 IgG, with enhanced ADCC
- VEGF trap



- Anti-PD-1 mAb with off-target VEGFR2 binding through same variable domains



- Anti-PD-1 IgG
- Novel anti-VEGF VHHs
- Inverted format



CRESCENT BIOPHARMA

Sources: Internal data; Summit Therapeutics 2023 SITC Poster; BioNTech 2024 ESMO Presentation; LaNova patent filings; Various patent filings; 2017 Lee (Scientific Reports); 2007 Rudge (PNAS)

CR-001 preclinical data reproduce ivonescimab's breakthro pharmacology & are rapidly advancing to generate significa

Unprecedented third-party data validate PD-1 x VEGF cooperativity

Ivonescimab significantly ***improved PFS versus pembrolizumab*** *in Phase 3 in 1L NSCLC – the first therapy to do so head-to-head.*

Transformative MoA for $50B+ market

Poised to ***transform*** *NSCLC* ***standard of care****, with broad application across $50B+ anti-PD-(L)1 market.*

CR-001's proprietary engineering is designed to replicate ivonescimab

CR-001 is a highly potent PD-1 x VEGF bsAb ***reproducing cooperative binding*** *qualities critical to ivonescimab.*

Promisin next-g

CR-002 ar complemen *opportunit*

CRESCENT BIOPHARMA

CR-002 & CR-003

Topoisomerase inhibitor ADCs against validated targets

CR-002 and CR-003 are potentially best-in-class topoisome inhibitor ADCs, with applicability across solid tumors

Validated, undisclosed solid tumor ADC targets

- Each unique target has **potential in multiple solid tumor** indications

Best-in-modality topoisomerase inhibitor payloads

- Topoisomerase inhibitor payloads have **consistently demonstrated superior efficacy and safety** over microtubule inhibitor payloads
- Each ADC is expected to have **bystander-killing effect**



Potential to synergiz and other immunoth

- Each ADC can be **lev combination studies**
- Multiple **indications (L)1 x VEGF bispeci** and ***separate*** **develo** help de-risk clinical p combinations

Targets for CR-002 and CR-003 **to be disclosed as programs approach IND**.

CRESCENT BIOPHARMA

ADCs with topoisomerase inhibitor payloads have demons best-in-modality efficacy and safety

CROSS-TRIAL C

Topo payload-based ADCs have **demonstrated superior ORR** vs. microtubule inhibitor-based ADCs in cross-trial comparisons…



… and have shown much **lower rates of periphe** critical AE that can **drive dose reductions & di**

	Target	Molecule	Phase	0 20
Topol payload	HER2	Enhertu	A	13%
	TROP2	Dato-DXd	R	2%
	HER3	Patritumab-DXd	R	0%
	B7-H3	Ifinatamab-DXd	3	0%
	CDH6	Raludotatug-DXd	2	0%
MT payload	CD30	Adcetris	A	
	Nectin-4	Padcev	A	
	TF	Tivdak	A	
	HER2	Kadcyla	A	16%
	HER2	Disitamab vedotin	3	

CR-002 and CR-003 utilize the **best-in-ADC payload in their potentially best-in-class profiles.**

CRESCENT BIOPHARMA

Notes: NSCLC = non-small cell lung cancer; GEJ = gastroesophageal junction; A = approved; R = in registration. PN rates are weighted averages, by number of patients, across indications / trials and include PN, PSN, PMN, and PSMN when separately measured; full list of trials and references available on request. Disitamab vedotin is approved in China and in Phase 3 development globally. Sources: Enhertu Label; 2024 Smit (Lancet Onc); Kadcyla Label; 2019 Peters (Clin Cancer Res); 2017 Thuss-Patience (Lancet Onc); 2024 Oaknin (ESMO Pres); 2024 Ahn (JCO); 2018 King (Invest New Drugs)

Corporate

Rapidly growing leadership team with deep experience buil the next generation of biotechnology companies

Jonathan Violin
Interim CEO
Board of Directors

Chris Doughty
Chief Business Officer

Peter Harwin
Board of Directors

Alex Balcom
Board of Directors

Susan
Board of D

VIRIDIAN Prometheus Biosciences APOGEE THERAPEUTICS SPYRE THERAPEUTICS astria THERAPEUTICS RαyzeBio Tre

ORUKA THERAPEUTICS DIANTHUS THERAPEUTICS Quellis STRATA cogent BIOSCIENCES Nuvalent agios TYRA

CRESCENT BIOPHARMA

Financing expected to fund Crescent programs through key anticipated value-generating catalysts

	2025		2026
CR-001 *(cooperative PD-1 x VEGF bsAb)*		**4Q25**: IND	**2H: Initial clinical data**
CR-002 *(undisclosed, ADC #1 with Topo I payload)*	2H: DC		**Mid-year: IND**
CR-003 *(undisclosed, ADC #2 with Topo I payload)*			1H: DC
Key external events	1H: BNT327 P2/3 EGFRm NSQ mNSCLC interim (China) 1H: Ivo P3 1L SQ mNSCLC interim (China) **2H: Ivo P3 HARMONi-2 1L mNSCLC OS (China)** 2H: BNT327 P2/3 1L ES-SCLC interim (China) 2H: Ivo P3 HARMONi EGFRm NSQ mNSCLC interim (global) 2H: Ivo P3 HARMONi-A EGFRm NSQ mNSCLC completion (China)		*Multiple P3 trials ongoing or planned (e.g., SCL with numerous PFS & OS readouts expected in*

CRESCENT BIOPHARMA

Notes: mNSCLC = metastatic non-small cell lung cancer; TNBC = triple negative breast cancer; SCLC = small cell lung cancer; ES = extensive stage. NSQ = non-squamous; SQ = squamous; EGFRm = mutant EGFR.
Sources: ClinicalTrials.gov; Company websites

Estimated capitalization following close of transactions

		Shares on an as-converted basis	Expected ownership of the combined company
GlycoMimetics	• Shares of common stock outstanding	64,532,953	3.1%
Crescent Biopharma	• Shares of common stock outstanding	105,137,814	96.9%
	• Series A shares	298,298,000	
Pre-closing financing	• Shares of common stock	1,339,680,730	
	• Pre-funded warrants	273,643,080	
Estimated total shares of common stock of the combined company post-closing		2,081,292,577	

CRESCENT BIOPHARMA


CRESCENT
BIOPHARMA
Thank you